SCHEMBL10153872

SCHEMBL10153872

Cc1ccc(OC(C)C)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 2/20 0.51
NPY1R P25929 1/20 0.51
NPY2R P49146 1/20 0.51
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 2/20 0.47
PARP10 Q53GL7 1/20 0.45
NPC1 O15118 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BRD4 O60885 1/20 0.44
BRPF1 P55201 1/20 0.44
ALDH1A3 P47895 1/20 0.43
POLB P06746 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
GLA P06280 1/20 0.41
ACACB O00763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10359371 0.82 TDP1 (0.63) TDP1SMN1; SMN2MAPTNPY1RNPY2R
SCHEMBL8534164 0.82 TDP1 (0.58) TDP1SMN1; SMN2MAPTNPY1RNPY2R
SCHEMBL8091598 0.82 TDP1 (0.58) TDP1SMN1; SMN2MAPTNPY1RNPY2R
SCHEMBL16481265 0.82 ALDH1A1 (0.46) TDP1SMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL12180740 0.82 ALDH1A1 (0.46) TDP1MAPTNPY1RNPY2RALDH1A1
SCHEMBL9946003 0.82 TDP1 (0.54) TDP1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL16606251 0.82 ALDH1A1 (0.46) TDP1MAPTNPY1RNPY2RALDH1A1
SCHEMBL11963662 0.80 ALDH1A1 (0.44) TDP1MAPTNPY1RNPY2RALDH1A1
SCHEMBL16756041 0.80 ALDH1A1 (0.46) TDP1MAPTNPY1RNPY2RALDH1A1
SCHEMBL3720563 0.80 ALDH1A1 (0.48) TDP1MAPTNPY1RNPY2RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024118607-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION, INC. (US) 2024-06-06 WO disclosed
EP-4253382-A1 NEW SMALL-MOLECULE COMPOUND FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTOR AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME S&K Therapeutics (KR) 2023-10-04 EP disclosed
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
US-20230043562-A1 COLORED RESIN COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-02-09 US disclosed
US-20200371435-A1 BLUE CURABLE RESIN COMPOSITION, BLUE COLOR FILTER, AND DISPLAY DEVICE INCLUDING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-11-26 US disclosed
EP-3719022-A1 POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE Janssen Pharmaceutica NV (BE) 2020-10-07 EP disclosed
EP-3386991-B1 POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE JANSSEN PHARMACEUTICA NV (BE) 2020-06-03 EP disclosed
US-10385070-B2 Chroman-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-20 US disclosed
WO-2018103060-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2018-06-14 WO disclosed
US-20090159130-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-25 US disclosed
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-18 US disclosed
US-20090145483-A1 Novel electroluminescent compounds and organic electroluminescent device suing the same GRACEL DISPLAY INC. (KR) 2009-06-11 US disclosed
US-20090078317-A1 Organometalic compounds for electroluminescence and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-03-26 US disclosed
US-20090029994-A1 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-29 US disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed
US-20080107608-A1 5-Substituted-2-Arylpyridines GE PING 2008-05-08 US disclosed
US-20080015196-A1 Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands NEUROGEN CORPORATION (US) 2008-01-17 US disclosed
WO-2007088996-A1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
US-7223778-B2 5-substituted-2-arylpyridines NEUROGEN CORPORATION (US) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 TDP1 2343/4885SMN1; SMN2 3040/4885MAPT 4236/4885
US-20090145483-A1 Novel electroluminescent compounds and organic electroluminescent device suing the same LEF1, ODC1, AOC2 TDP1 2726/4885SMN1; SMN2 3747/4885MAPT 2579/4885
US-20090078317-A1 Organometalic compounds for electroluminescence and organic electroluminescent device using the same OCIAD1, L1CAM, OCIAD2 TDP1 2344/4885SMN1; SMN2 3641/4885MAPT 2039/4885
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same NDUFS2, ALDH1A2, ODC1 TDP1 2777/4885SMN1; SMN2 4625/4885MAPT 1708/4885
US-20090159130-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, LEF1, ODC1 TDP1 2124/4885SMN1; SMN2 4652/4885MAPT 2613/4885
US-20080015196-A1 Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands CRHR1, CRHR2, CRHBP TDP1 1923/4885SMN1; SMN2 811/4885MAPT 3153/4885
US-20090029994-A1 Trisubstituted amine compound CETP, MTTP, APOB TDP1 1348/4885SMN1; SMN2 4864/4885MAPT 2667/4885
US-20080107608-A1 5-Substituted-2-Arylpyridines CRHR2, CRHR1, HTR2C TDP1 2732/4885SMN1; SMN2 1354/4885MAPT 2953/4885
US-10385070-B2 Chroman-spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ1, KCNC1 TDP1 3694/4885SMN1; SMN2 1515/4885MAPT 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.